Aqualung Therapeutics featured as a presenter at GatorPitch Jupiter, placing the company directly in front of a room filled with investors, venture partners, and biotech leaders actively looking for the next wave of high impact science.
“The event features University of Florida startup pitches, a research showcase and a venture capital panel of top industry experts.”
As part of the March 5, 2026 event hosted at the Herbert Wertheim UF Scripps Institute in Jupiter, Aqualung joined a select group of University of Florida affiliated startups chosen to showcase technologies advancing drug discovery and human health. The event is not just a pitch competition, it is a curated platform. Companies are vetted, mentored, and then positioned to present to serious capital. Being included signals that Aqualung is viewed as a credible, investment ready player within UF’s biotech ecosystem.
During the program, Aqualung had the opportunity to present its platform and pipeline to investors connected to firms like ARCH Venture Partners, Ascenta Capital, Mission BioCapital, and Curie.Bio. That matters. These are not passive audiences, they are groups that fund and scale companies in exactly this space. The exposure alone is valuable, but the real upside is access to follow up conversations that can drive partnerships, funding, and long term growth.
The Jupiter expansion of GatorPitch is also relevant context. This is the first time the event leaned fully into biotechnology, and it was intentionally held at UF Scripps, a hub for translational science. Aqualung presenting in that setting reinforces its positioning as a company grounded in serious science with a clear path toward clinical and commercial impact.
Aqualung was placed in a high visibility, high credibility environment designed to connect strong science with capital. That is exactly where an early stage therapeutics company needs to be.